This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation
- Associations between Cancer-Related Information Seeking and Receiving PET Imaging for Routine Cancer Surveillance--An Analysis of Longitudinal Survey Data
- Beta-2 Microglobulin as a Diagnostic Parameter in Non-Hodgkin Lymphoma: A Comparative Study with FDG-PET
- [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Breast Cancer: When... and When Not?
- Invasive Breast Cancer
- Targeting the {alpha}v{beta}3 Integrin for Small-Animal PET/CT of Osteolytic Bone Metastases
- The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1--Overview, Detection, and Staging
- Breast Cancer
- Infrequently Performed Studies in Nuclear Medicine: Part 1
- Is There a Role for Positron Emission Tomography in Breast Cancer Staging?
- FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy
- Comparison of 18F-FDG PET and Bone Scintigraphy in Detection of Bone Metastases of Thyroid Cancer
- Improving Specificity of Breast MRI Using Prone PET and Fused MRI and PET 3D Volume Datasets
- Sequential Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Response to Chemotherapy in Metastatic Breast Cancer.
- 18F-FDG PET for Staging Breast Cancer in Patients with Inner-Quadrant Versus Outer-Quadrant Tumors: Comparison with Long-Term Clinical Outcome
- Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities
- Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
- Bone Imaging in Metastatic Breast Cancer
- Evaluation of 18F-FDG PET in Patients with Advanced, Metastatic, or Recurrent Gastric Cancer
- Whole-Body 18F-FDG PET and Conventional Imaging for Predicting Outcome in Previously Treated Breast Cancer Patients
- 18Fluorodeoxyglucose Positron Emission Tomography to Detect Mediastinal or Internal Mammary Metastases in Breast Cancer
- Impact of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography on Patient Management: First Year's Experience in a Clinical Center
- A Tabulated Summary of the FDG PET Literature
- The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology
- Limited Angle, Limited Approach?
- Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and Limitations
- Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer